Bullish Outlook on Werewolf Therapeutics: Unveiling the Potential of WTX-124 as a Best-in-Class IL-2 Therapy
BofA Securities Maintains Werewolf Therapeutics(HOWL.US) With Buy Rating, Maintains Target Price $10
BofA Securities analyst Jason Zemansky maintains $Werewolf Therapeutics(HOWL.US)$ with a buy rating, and maintains the target price at $10.According to TipRanks data, the analyst has a success rate of
JMP Securities Maintains Werewolf Therapeutics(HOWL.US) With Buy Rating, Maintains Target Price $12
JMP Securities analyst Reni Benjamin maintains $Werewolf Therapeutics(HOWL.US)$ with a buy rating, and maintains the target price at $12.According to TipRanks data, the analyst has a success rate of 3
Werewolf Therapeutics Says Initial Data Show Potential Non-Hodgkin Lymphoma Treatment Increased Therapeutic Window in Phase 1 Clinical Trial
Werewolf Therapeutics (HOWL) said Tuesday that initial results showed that potential non-Hodgkin lymphoma treatment WTX-330 increased therapeutic window in a phase 1 clinical trial. The company also s
Express News | Werewolf Therapeutics Announced Initial Results From Phase 1 Trial Of WTX-330 As Monotherapy For Immunotherapy Insensitive Or Resistant Locally Advanced Or Metastatic Solid Tumors Or Non-Hodgkin Lymphoma, Additional Results Expected In Q4 Of 2024
Express News | Werewolf Therapeutics: Results Showed Encouraging Signals of Clinical Activity
Express News | Werewolf Therapeutics Highlights Initial Safety and Efficacy Data From Its Ongoing Phase 1 Clinical Trial Evaluating Wtx-330 in Patients With Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma
Werewolf Therapeutics, Inc.'s (NASDAQ:HOWL) 40% Dip Still Leaving Some Shareholders Feeling Restless Over Its P/SRatio
To the annoyance of some shareholders, Werewolf Therapeutics, Inc. (NASDAQ:HOWL) shares are down a considerable 40% in the last month, which continues a horrid run for the company. The last month h
Express News | JMP Securities Reiterates Market Outperform on Werewolf Therapeutics, Maintains $12 Price Target
12 Health Care Stocks Moving In Monday's Intraday Session
GainersStructure Therapeutics (NASDAQ:GPCR) stock moved upwards by 71.0% to $58.47 during Monday's regular session. The market value of their outstanding shares is at $2.7 billion. Concord Medical Ser
Analysts Offer Insights on Healthcare Companies: Werewolf Therapeutics (HOWL), Eli Lilly & Co (LLY) and Envista Holdings (NVST)
Express News | Werewolf Therapeutics: Wtx-124 Shown to Be Clinically Active and Generally Well-Tolerated in Patients
Express News | Werewolf Therapeutics to Present Data From Ongoing Phase 1/1B Clinical Trial of Wtx-124 as Monotherapy and in Combination With Pembrolizumab in Solid Tumors
Werewolf Therapeutics to Present Data From Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination With Pembrolizumab in Solid Tumors
- WTX-124 was shown to be clinically active and generally well-tolerated in patients who were relapsed/refractory to immune checkpoint inhibitor therapy - - Encouraging single agent clinical activity with three
Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference
WATERTOWN, Mass., May 30, 2024 (GLOBE NEWSWIRE) -- Werewolf Therapeutics, Inc. (the "Company" or "Werewolf") (Nasdaq: HOWL), an innovative biopharmaceutical company pioneering the development of con
Analysts' Top Healthcare Picks: Axsome Therapeutics (AXSM), Werewolf Therapeutics (HOWL)
Critical Insights From Werewolf Therapeutics Analyst Ratings: What You Need To Know
In the latest quarter, 5 analysts provided ratings for Werewolf Therapeutics (NASDAQ:HOWL), showcasing a mix of bullish and bearish perspectives.The table below summarizes their recent ratings, showca
H.C. Wainwright Maintains Werewolf Therapeutics(HOWL.US) With Buy Rating, Maintains Target Price $15
H.C. Wainwright analyst Andres Y. Maldonado maintains $Werewolf Therapeutics(HOWL.US)$ with a buy rating, and maintains the target price at $15.According to TipRanks data, the analyst has a success ra
Buy Rating Justified by Werewolf Therapeutics' Advancements in WTX-124 With Promising Efficacy and Safety Profile
Werewolf Therapeutics to Present Updated Data From Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination With Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting
- Updated single agent dose escalation data continues to demonstrate that WTX-124 is well tolerated and clinically active in patients with checkpoint inhibitor therapy relapsed/refractory cancers - - Preliminary data